5. Adjuvant therapy after SCS
35 (67.3%) patients received adjuvant chemotherapy after SCS (Table 4). The most common chemotherapy regimen was doxorubicin-based treatment, followed by gemcitabine/docetaxel regimen. 1 (1.9%) patient with vaginal cuff recurrent received pelvic radiotherapy. 1 (1.9%) patient received pazopanib treatment. 16 (30.8%) patients did not receive any adjuvant therapy after SCS.
6. Non-secondary cytoreductive surgery treatment
Among patients received non-secondary cytoreductive surgery treatment, 14 (73.7%) patients received chemotherapy, 2 (10.5%) patients received chemotherapy and pelvic radiotherapy, 1 (5.3%) patient received anlotinib treatment, and 2 (10.5%) patients refused cancer treatment (Table S1). 16 patients died during follow-up.